Abstract
Background: Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs.
Method: However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may provide an alternative to opioids for the treatment of pain. However, systemically administered conventional benzodiazepines fail to produce antihyperalgesic effects, likely due to their concurrent sedative properties. Results: Recent evidence suggests that by targeting specific benzodiazepine-sensitive GABAA receptor subtypes, the sedative properties of benzodiazepines can be circumvented and these compounds may be useful alternatives to opioids for the treatment of chronic pain. Conclusion: The present review provides an overview of the GABAA receptor subtypes involved in pain transmission as well as implications for the development of analgesic medications.Keywords: Antihyperalgesic, benzodiazepine, drug development, disorders, GABAA, pain.
CNS & Neurological Disorders - Drug Targets
Title:GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update
Volume: 16 Issue: 6
Author(s): Bradford D. Fischer*
Affiliation:
- Cooper Medical School of Rowan University, Camden, NJ,United States
Keywords: Antihyperalgesic, benzodiazepine, drug development, disorders, GABAA, pain.
Abstract: Background: Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs.
Method: However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may provide an alternative to opioids for the treatment of pain. However, systemically administered conventional benzodiazepines fail to produce antihyperalgesic effects, likely due to their concurrent sedative properties. Results: Recent evidence suggests that by targeting specific benzodiazepine-sensitive GABAA receptor subtypes, the sedative properties of benzodiazepines can be circumvented and these compounds may be useful alternatives to opioids for the treatment of chronic pain. Conclusion: The present review provides an overview of the GABAA receptor subtypes involved in pain transmission as well as implications for the development of analgesic medications.Export Options
About this article
Cite this article as:
Fischer D. Bradford*, GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update, CNS & Neurological Disorders - Drug Targets 2017; 16 (6) . https://dx.doi.org/10.2174/1871527316666170207155149
DOI https://dx.doi.org/10.2174/1871527316666170207155149 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets Amiodarone-Induced SIADH: Two Cases Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Alternative Therapies for Diabetes: A Comparison of Western and Traditional Chinese Medicine (TCM) Approaches
Current Diabetes Reviews From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches
Current Pharmaceutical Design Diabetes, Hyperglycemia and Accelerated Atherosclerosis: Evidence Supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Nano-biotechnology and its Innovative Perspective in Diabetes Management
Mini-Reviews in Medicinal Chemistry Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum
Current Drug Safety Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis
Current Diabetes Reviews Subject Index to Volume 10
Current Medicinal Chemistry Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Conotoxins: Structure, Therapeutic Potential and Pharmacological Applications
Current Pharmaceutical Design